Bristol Myers Squibb Canada (BMS) is pleased to announce an update to the Canadian product monograph for BREYANZI® (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor T (CAR T) cell therapy, reducing the duration of certain post-treatment monitoring and activity restrictions for eligible patients following infusion.

The updated guidance includes a reduction in the recommended duration for patients to remain in close proximity to a specialized treatment centre from 28 days to 14 days following infusion, as well as a reduction in driving restrictions from eight weeks to four weeks. Clinical decisions regarding patient discharge and ongoing monitoring will continue to be determined by the treating healthcare professional based on individual patient needs.